PharmaMar con Cuatro Fármacos ( Yondelis , Aplidin , Zepsyre y Plocabulin ) está Contribuyendo , Liderando y Enriqueciendo la Farmacología del Cáncer con Medicamentos de Origen Marino .

Enriching Cancer Pharmacology with Drugs of Marine Origin .

British Journal of Pharmacology . 17 October 2019. 

Paula C. Jimenez Diego V. Wilke Paola C. Branco Anelize Bauermeister …

Abstract :

Marine natural products have proven, over the last half‐century, to be effective biological modulators. These molecules have revealed new targets for cancer therapy as well as dissimilar modes of action within typical classes of drugs. In this scenario, innovation from marine‐based pharmaceuticals has helped advance cancer chemotherapy in many aspects, as most of these are designated as first‐in‐class drugs. Herein, by examining the path from discovery to development of clinically approved drugs of marine origin for cancer treatment – cyrabine (Cytosar‐U®), trabectedin (Yondelis®), eribulin (Halaven®), brentuximab vedotin (Adcetris®) and plitidepsin (Aplidin®) – plus those in late clinical trial phases – lurbinectedin, plinabulin, marizomib and plocabulin –, the present review offers a critical analysis of the contributions given by these new compounds to cancer pharmacotherapy.